Stock Traders Purchase High Volume of Call Options on DexCom (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the target of some unusual options trading on Monday. Traders acquired 14,972 call options on the stock. This is an increase of 120% compared to the average volume of 6,802 call options.

Insider Buying and Selling at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total transaction of $113,550.00. Following the sale, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, Director Bridgette P. Heller sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Jereme M. Sylvain sold 745 shares of the company’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $115.05, for a total value of $85,712.25. Following the completion of the transaction, the chief financial officer now directly owns 84,948 shares in the company, valued at $9,773,267.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,112 shares of company stock valued at $480,861. 0.30% of the stock is currently owned by corporate insiders.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Capital World Investors increased its position in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after acquiring an additional 5,256,092 shares during the period. Norges Bank purchased a new position in shares of DexCom during the fourth quarter worth approximately $540,178,000. Artisan Partners Limited Partnership increased its position in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after acquiring an additional 3,672,471 shares during the period. Capital Research Global Investors increased its position in shares of DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after acquiring an additional 2,695,296 shares during the period. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of DexCom during the fourth quarter worth approximately $231,773,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of research reports. BTIG Research decreased their target price on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research note on Friday. Morgan Stanley reduced their price objective on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research note on Friday. UBS Group reduced their price objective on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday. Stifel Nicolaus dropped their target price on shares of DexCom from $132.00 to $90.00 and set a “buy” rating for the company in a report on Friday. Finally, JPMorgan Chase & Co. downgraded shares of DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $145.00 to $75.00 in a report on Friday. Seven analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $113.06.

DexCom Trading Up 6.3 %

DexCom stock traded up $4.00 during midday trading on Monday, reaching $68.00. The stock had a trading volume of 8,190,021 shares, compared to its average volume of 3,312,346. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. DexCom has a 52-week low of $62.34 and a 52-week high of $142.00. The firm has a market cap of $27.25 billion, a price-to-earnings ratio of 43.45, a price-to-earnings-growth ratio of 1.58 and a beta of 1.16. The company has a fifty day moving average of $115.28 and a 200 day moving average of $123.76.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same period in the prior year, the company posted $0.34 EPS. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. On average, analysts anticipate that DexCom will post 1.76 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.